138 related articles for article (PubMed ID: 38557857)
41. The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation.
Battistella S; Zanetto A; Gambato M; Germani G; Senzolo M; Burra P; Russo FP
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243124
[TBL] [Abstract][Full Text] [Related]
42. Prevention of hepatitis B virus reinfection in liver transplant recipients.
Roche B; Samuel D
Intervirology; 2014; 57(3-4):196-201. PubMed ID: 25034488
[TBL] [Abstract][Full Text] [Related]
43. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
[TBL] [Abstract][Full Text] [Related]
44. Hepatitis B Immunoglobulin discontinuation in long-term liver transplant patients.
Dobrindt EM; Keshi E; Salim Y; Gillespie A; Saipbaev A; Schöning W; Öllinger R; Pratschke J; Eurich D
Transpl Infect Dis; 2020 Aug; 22(4):e13303. PubMed ID: 32367631
[TBL] [Abstract][Full Text] [Related]
45. Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin.
Ahn J; Cohen SM
Hepat Mon; 2011 Aug; 11(8):638-45. PubMed ID: 22140388
[TBL] [Abstract][Full Text] [Related]
46. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation.
Cholongitas E; Papatheodoridis GV
World J Gastroenterol; 2013 Dec; 19(48):9189-97. PubMed ID: 24409047
[TBL] [Abstract][Full Text] [Related]
47. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
48. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
[TBL] [Abstract][Full Text] [Related]
49. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
Stärkel P; Stoffel M; Lerut J; Horsmans Y
Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
[TBL] [Abstract][Full Text] [Related]
50. Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database.
Park GC; Hwang S; Kim MS; Jung DH; Song GW; Lee KW; Kim JM; Lee JG; Ryu JH; Choi DL; Wang HJ; Kim BW; Kim DS; Nah YW; You YK; Kang KJ; Yu HC; Park YH; Lee KJ; Kim YK
J Korean Med Sci; 2020 Feb; 35(6):e36. PubMed ID: 32056398
[TBL] [Abstract][Full Text] [Related]
51. Antiviral Combination Therapy With Low-Dose Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Virus Recurrence in Liver Transplant Recipients: A Single-Center Experience.
Akcam AT; Ulku A; Rencuzogullari A; Eray IC; Okoh A; Kuran S; Dalcı K; Yalav O; Parsak CK; Sakman G; Demiryurek H
Transplant Proc; 2015 Jun; 47(5):1445-9. PubMed ID: 26093739
[TBL] [Abstract][Full Text] [Related]
52. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis B and liver transplantation: 2008 update.
Beckebaum S; Sotiropoulos GC; Gerken G; Cicinnati VR
Rev Med Virol; 2009 Jan; 19(1):7-29. PubMed ID: 18816503
[TBL] [Abstract][Full Text] [Related]
54. Recurrence of Hepatitis D Virus in Liver Transplant Recipients With Hepatitis B and D Virus-Related Chronic Liver Disease.
Serin A; Tokat Y
Transplant Proc; 2019 Sep; 51(7):2457-2460. PubMed ID: 31405744
[TBL] [Abstract][Full Text] [Related]
55. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients.
Weber NK; Forman LM; Trotter JF
Dig Dis Sci; 2010 Feb; 55(2):505-9. PubMed ID: 19802696
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation.
Ku W; Wang U; Nguyen MH
Expert Opin Biol Ther; 2015 May; 15(5):665-77. PubMed ID: 25865452
[TBL] [Abstract][Full Text] [Related]
57. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative.
Geng L; Lin BY; Shen T; Guo H; Ye YF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):316-8. PubMed ID: 27298109
[TBL] [Abstract][Full Text] [Related]
58. High-potency nucleos(t)ide analogues alone or plus immunoglobulin for HBV prophylaxis after liver transplantation: a meta-analysis.
Sheng LP; Zhang JC; Zhong ZQ; Sheng XH; Ren J; Wang GQ
Hepatol Int; 2023 Oct; 17(5):1113-1124. PubMed ID: 36592270
[TBL] [Abstract][Full Text] [Related]
59. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
Sánchez-Fueyo A; Rimola A; Grande L; Costa J; Mas A; Navasa M; Cirera I; Sánchez-Tapias JM; Rodés J
Hepatology; 2000 Feb; 31(2):496-501. PubMed ID: 10655276
[TBL] [Abstract][Full Text] [Related]
60. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
Patterson SJ; Angus PW
Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
